Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines
Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding.
The COVID-19 pandemic demonstrated the promise of using mRNA as medicine. But before mRNA drugs can go beyond vaccines, researchers need to identify the right diseases to treat.
SOUTH SAN FRANCISCO, Calif., January 03, 2024 Switch Therapeutics today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).
From COVID-19 vaccines to cancer treatments and beyond, the flexibility of mRNA-based therapies gives them the potential to prevent and treat many types of diseases.